Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Sep;74(6):956–960. doi: 10.1038/bjc.1996.464

Preoperative CYFRA 21-1 level as a prognostic indicator in resected primary squamous cell lung cancer.

J Niklinski 1, M Furman 1, T Burzykowski 1, L Chyczewski 1, J Laudanski 1, E Chyczewska 1, M Rapellino 1
PMCID: PMC2074750  PMID: 8826865

Abstract

The CYFRA 21-1 assay is a test that has been developed recently for detection of a cytokeratin 19 fragment in serum. A diagnostic role for CYFRA 21-1 has already been proposed. The question of whether this marker is prognostically significant is important in clarifying the role of CYFRA 21-1 in clinical practice. The aim of this study was to evaluate the prognostic significance of elevated preoperative CYFRA 21-1 levels in patients with resected primary squamous-cell lung cancer (SqCC). Serum levels of CYFRA 21-1 were measured using an immunoradiometric assay (CIS bio) in 91 patients with operable SqCC. Survival and disease-free survival curves related to initial levels of this marker were estimated using the Kaplan-Meier method. In the univariate analysis the log-rank test and the log-rank test for trend were used. In the multivariate analysis the stratified log-rank test and the proportional hazard model were used. Elevated preoperative CYFRA 21-1 levels were identified in 55% of patients with SqCC. The number of patients with elevated levels of this marker increased with TNM stage (P = 0.0001). In univariate analysis elevated levels of CYFRA 21-1 were significantly associated with poor overall survival (P < 0.00005) and with disease-free survival (P < 0.00005). In multivariate analysis elevated levels of this marker were also found to be associated with poor overall and disease-free survival (P = 0.01 and P = 0.003 respectively). In conclusion, CYFRA 21-1 may be an independent prognostic parameter of survival and tumour relapse in SqCC and may be useful in identifying resected SqCC patients at high risk of treatment failure.

Full text

PDF
957

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bodenmüller H., Ofenloch-Hähnle B., Lane E. B., Dessauer A., Böttger V., Donié F. Lung cancer-associated keratin 19 fragments: development and biochemical characterisation of the new serum assay Enzymun-Test CYFRA 21-1. Int J Biol Markers. 1994 Apr-Jun;9(2):75–81. doi: 10.1177/172460089400900203. [DOI] [PubMed] [Google Scholar]
  2. Broers J. L., Ramaekers F. C., Rot M. K., Oostendorp T., Huysmans A., van Muijen G. N., Wagenaar S. S., Vooijs G. P. Cytokeratins in different types of human lung cancer as monitored by chain-specific monoclonal antibodies. Cancer Res. 1988 Jun 1;48(11):3221–3229. [PubMed] [Google Scholar]
  3. Buccheri G., Ferrigno D. Prognostic factors in lung cancer: tables and comments. Eur Respir J. 1994 Jul;7(7):1350–1364. doi: 10.1183/09031936.94.07071350. [DOI] [PubMed] [Google Scholar]
  4. Ebert W., Bodenmüller H., Hölzel W. CYFRA 21-1--clinical applications and analytical requirements. Scand J Clin Lab Invest Suppl. 1995;221:72–80. doi: 10.3109/00365519509090568. [DOI] [PubMed] [Google Scholar]
  5. Fielding L. P., Fenoglio-Preiser C. M., Freedman L. S. The future of prognostic factors in outcome prediction for patients with cancer. Cancer. 1992 Nov 1;70(9):2367–2377. doi: 10.1002/1097-0142(19921101)70:9<2367::aid-cncr2820700927>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  6. Moll R., Franke W. W., Schiller D. L., Geiger B., Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982 Nov;31(1):11–24. doi: 10.1016/0092-8674(82)90400-7. [DOI] [PubMed] [Google Scholar]
  7. Moll R., Schiller D. L., Franke W. W. Identification of protein IT of the intestinal cytoskeleton as a novel type I cytokeratin with unusual properties and expression patterns. J Cell Biol. 1990 Aug;111(2):567–580. doi: 10.1083/jcb.111.2.567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Mountain C. F. New prognostic factors in lung cancer. Biologic prophets of cancer cell aggression. Chest. 1995 Jul;108(1):246–254. doi: 10.1378/chest.108.1.246. [DOI] [PubMed] [Google Scholar]
  9. Nagle R. B. Intermediate filaments: a review of the basic biology. Am J Surg Pathol. 1988;12 (Suppl 1):4–16. [PubMed] [Google Scholar]
  10. Niklinski J., Furman M., Chyczewska E., Chyczewski L., Rogowski F., Jaroszewicz E., Laudanski J. Evaluation of CYFRA 21-1 as a new marker for non-small cell lung cancer. Eur J Cancer Prev. 1994 Mar;3(2):227–230. doi: 10.1097/00008469-199403000-00009. [DOI] [PubMed] [Google Scholar]
  11. Niklinski J., Furman M., Chyczewska E., Chyczewski L., Rogowski F., Laudanski J. Diagnostic and prognostic value of the new tumour marker CYFRA 21-1 in patients with squamous cell lung cancer. Eur Respir J. 1995 Feb;8(2):291–294. doi: 10.1183/09031936.95.08020291. [DOI] [PubMed] [Google Scholar]
  12. Niklinski J., Furman M. Clinical tumour markers in lung cancer. Eur J Cancer Prev. 1995 Apr;4(2):129–138. doi: 10.1097/00008469-199504000-00002. [DOI] [PubMed] [Google Scholar]
  13. Paone G., De Angelis G., Munno R., Pallotta G., Bigioni D., Saltini C., Bisetti A., Ameglio F. Discriminant analysis on small cell lung cancer and non-small cell lung cancer by means of NSE and CYFRA-21.1. Eur Respir J. 1995 Jul;8(7):1136–1140. doi: 10.1183/09031936.95.08071136. [DOI] [PubMed] [Google Scholar]
  14. Pujol J. L., Grenier J., Daurès J. P., Daver A., Pujol H., Michel F. B. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res. 1993 Jan 1;53(1):61–66. [PubMed] [Google Scholar]
  15. Rapellino M., Niklinski J., Pecchio F., Furman M., Baldi S., Chyczewski L., Ruffini E., Chyczewska E. CYFRA 21-1 as a tumour marker for bronchogenic carcinoma. Eur Respir J. 1995 Mar;8(3):407–410. doi: 10.1183/09031936.95.08030407. [DOI] [PubMed] [Google Scholar]
  16. Rastel D., Ramaioli A., Cornillie F., Thirion B. CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation. CYFRA 21-1 Multicentre Study Group. Eur J Cancer. 1994;30A(5):601–606. doi: 10.1016/0959-8049(94)90528-2. [DOI] [PubMed] [Google Scholar]
  17. Richardson G. E., Johnson B. E. The biology of lung cancer. Semin Oncol. 1993 Apr;20(2):105–127. [PubMed] [Google Scholar]
  18. Stieber P., Hasholzner U., Bodenmüller H., Nagel D., Sunder-Plassmann L., Dienemann H., Meier W., Fateh-Moghadam A. CYFRA 21-1. A new marker in lung cancer. Cancer. 1993 Aug 1;72(3):707–713. doi: 10.1002/1097-0142(19930801)72:3<707::aid-cncr2820720313>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  19. Wieskopf B., Demangeat C., Purohit A., Stenger R., Gries P., Kreisman H., Quoix E. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role. Chest. 1995 Jul;108(1):163–169. doi: 10.1378/chest.108.1.163. [DOI] [PubMed] [Google Scholar]
  20. van der Gaast A., Schoenmakers C. H., Kok T. C., Blijenberg B. G., Cornillie F., Splinter T. A. Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1. Br J Cancer. 1994 Mar;69(3):525–528. doi: 10.1038/bjc.1994.95. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES